Back to top
more

Sanofi (SNY)

(Delayed Data from NSDQ)

$51.20 USD

51.20
2,122,230

+0.77 (1.53%)

Updated Jul 24, 2024 04:00 PM ET

After-Market: $51.22 +0.02 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lilly (LLY) Q2 Earnings Top, Baricitinib Re-Filing Delayed

by Zacks Equity Research

Eli Lilly and Company (LLY) beat estimates for both sales and earnings in Q2 and upped its 2017 outlook. However, it said the NDA resubmission for baricitinib will not occur this year, which hurt shares.

    Merck's Biosimilar Insulin Gets Tentative FDA Approval

    by Zacks Equity Research

    Merck (MRK) secures a tentative FDA approval for its insulin candidate, Lusduna Nexvue, a biosimilar version of Sanofi's Lantus. The sanction is provisional owing to an ongoing litigation with Sanofi.

      Arpita Dutt headshot

      Pharma Stock Roundup: J&J, NVS' Q2 Earnings, Merck Drug Gets Tentative FDA Nod

      by Arpita Dutt

      Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.

        Sarepta & BioMarin Settle Patent Litigation on Exon Skipping

        by Zacks Equity Research

        Sarepta Therapeutics, Inc. (SRPT), and BioMarin Pharmaceutical Inc., have settled their ongoing global patent litigation pertaining to exon skipping technology used in Duchenne muscular dystrophy therapies.

          Valeant (VRX) To Sell Obagi for $190 Million to Lower Debt

          by Zacks Equity Research

          Valeant (VRX) has decided to sell Obagi Medical for $190 million and use the proceeds for reducing down debt.

            Is a Beat in the Cards for Eli Lilly (LLY) in Q2 Earnings?

            by Zacks Equity Research

            Eli Lilly and Company's (LLY) new drugs like Trulicity, Cyramza, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

              Perrigo Company Gets FDA Approval for Generic Topical Gel

              by Zacks Equity Research

              Perrigo Company plc (PRGO) receives approval from the FDA for generic version of Androgel Topical Gel, for replacement therapy in males.

                Sheraz Mian headshot

                Early Read on the Q2 Earnings Season

                by Sheraz Mian

                I am reasonably confident that we are on our way for another reassuring earnings read.

                  AstraZeneca (AZN) CEO Rumor Reportedly Ends, Shares Rise

                  by Zacks Equity Research

                  AstraZeneca plc shares rose after the company reportedly confirmed that its CEO is not quitting the company to join the generic drug-maker, Teva Pharmaceutical Industries Limited (TEVA).

                    Swarup Gupta headshot

                    Foreign Stock Roundup: Infosys Beats, Taiwan Semiconductor Misses

                    by Swarup Gupta

                    Dovish comments from Yellen helped global stocks post gains.

                      Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit

                      by Zacks Equity Research

                      Emergent BioSolutions Inc. (EBS) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine's business of Sanofi (SNY) in an all-cash deal of up to $125 million.

                        Pfizer Xeljanz Label Expansion Application Accepted by FDA

                        by Zacks Equity Research

                        Pfizer Inc.'s (PFE) supplemental new drug application (sNDA) for Xeljanz has been accepted for review by the FDA.

                          Arpita Dutt headshot

                          Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

                          by Arpita Dutt

                          Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

                            Mallinckrodt's MNK-1411 Gets Orphan Drug Status for DMD

                            by Zacks Equity Research

                            Mallinckrodt plc (MNK) announced that the FDA has granted orphan drug designation to its pipeline candidate - MNK-1411, which is being evaluated for the treatment of Duchenne muscular dystrophy (DMD).

                              Lilly Settles Patent Litigation on Cialis with Generic Firms

                              by Zacks Equity Research

                              Eli Lilly & Company (LLY) announced that it has entered into an agreement with generic companies to settle a patent relating to its erectile dysfunction drug Cialis (tadalafil).

                                Endocyte (ECYT) to Focus on Promising CAR-T Cell Platform

                                by Zacks Equity Research

                                We issued an updated research report Endocyte, Inc. (ECYT) on Jul 12.

                                  Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth

                                  by Zacks Equity Research

                                  On Jul 11, Alnylam Pharmaceuticals Inc. (ALNY) was upgraded to a Zacks Rank #2 (Buy).

                                    Alnylam (ALNY) Stock Down Despite Positive Hemophilia Data

                                    by Zacks Equity Research

                                    Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) specialty care global business unit, Genzyme, announced encouraging results from the ongoing phase II open-label extension (OLE) study.

                                      Sanofi to Buy Vaccine Biotech Protein Sciences for $650M

                                      by Zacks Equity Research

                                      Sanofi (SNY), on Monday, announced plans to buy a Meriden, CT-based private vaccine biotech, Protein Sciences for an upfront payment of $650 million.

                                        Are Medicines Company's Key Drugs Set for Growth in 2017?

                                        by Zacks Equity Research

                                        On Jul 7, 2017, we issued an updated report on The Medicines Company (MDCO).

                                          Alnylam Commences Phase III Study for Hemophilia Candidate

                                          by Zacks Equity Research

                                          Alnylam Pharmaceuticals, Inc. (ALNY) and Sanofi's (SNY) announced that it has commenced phase III ATLAS study for its candidate fitusiran.

                                            Endo (ENDP) to Remove Opioid Pain Drug Opana ER from Market

                                            by Zacks Equity Research

                                            Endo International plc (ENDP) recently announced that it will withdraw opioid pain medication Opana ER (oxymorphone hydrochloride extended release) from the market following FDA's request in June.

                                              Sanofi Versus AstraZeneca: Large Cap Pharma Stock Faceoff

                                              by Zacks Equity Research

                                              Both stocks carry a Zacks Rank #2 (Buy).

                                                ProQR's Usher Syndrome Candidate Gets Orphan Drug Status

                                                by Zacks Equity Research

                                                ProQR Therapeutics N.V. (PRQR) announced that its key pipeline candidate, QRX-411, has been granted orphan drug designation by the FDA and European Medicines Agency (EMA) for the treatment of retinitis pigmentosa.

                                                  Sucampo (SCMP) Remains Focused on Amitza Label Expansion

                                                  by Zacks Equity Research

                                                  We issued an updated report on Sucampo Pharmaceuticals, Inc. (SCMP) on July 4.